Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report.
Lucia TruduGiorgia GuaitoliFederica BertoliniMichela MaurChiara SantiniVito Roberto PapapietroSabrina TalericoSalvatore NatalizioChrystel IscaMassimo DominiciFausto BarbieriPublished in: Immunotherapy (2022)
Introduction : Aims of the study were to explore outcomes and toxicities of chemotherapy-immunotherapy (CT-IT) for patients (pts) with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) in a real-world population. Materials & methods: Clinical data of 26 pts with mNSCLC treated with CT-IT at our institution from January 2020 to January 2021 were collected retrospectively. Results: Median follow-up time was 7.7 months. Median progression-free survival was 9.5 months. The most frequent immune-related adverse event was thyroid dysfunction (ThD): 30.7%. Conclusion: There was a higher rate of ThD in this study population compared with the literature, with a possible correlation with clinical outcomes.
Keyphrases
- small cell lung cancer
- free survival
- end stage renal disease
- computed tomography
- newly diagnosed
- squamous cell carcinoma
- chronic kidney disease
- systematic review
- oxidative stress
- magnetic resonance imaging
- prognostic factors
- positron emission tomography
- electronic health record
- skeletal muscle
- metabolic syndrome
- radiation therapy
- adipose tissue
- cancer therapy
- cross sectional
- brain metastases
- insulin resistance
- artificial intelligence
- patient reported
- data analysis
- patient reported outcomes